Drugs / Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes
Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00509288 | Jun 2007 → Jul 2011 | melanoma, skin cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00509288 ↗ |
| Action | Deplete | “anti-MART-1 F5 TCR transduced T-cells could efficiently kill HLA-A\*0201 positive tumors” NCT00509288 ↗ |
| Modality | Cell therapy | “gene-engineered tumor infiltrating lymphocytes” NCT00509288 ↗ |
| Route | Intravenous | “Cells will be infused intravenously (i.v.).” NCT00509288 ↗ |